Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.64 |
| ▸ | FPR1 | P21462 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061034 | 1.00 | KDM4E (0.78) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL14458153 | 0.91 | KCNA5 (0.67) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL12201417 | 0.91 | MEN1 (0.76) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL23200258 | 0.89 | KMT2A (0.67) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL25060949 | 0.83 | KCNA5 (0.61) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL23412943 | 0.82 | ALDH1A1 (0.68) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL30093086 | 0.82 | ALDH1A1 (0.68) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL5270827 | 0.82 | KMT2A (0.58) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL1688339 | 0.81 | METAP2 (0.71) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7572268 | 0.81 | KDM4E (0.69) | KDM4EMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4140991-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2023-03-01 | — | — | EP | claimed |
| US-20220365086-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORPORATION | 2022-11-17 | — | — | US | claimed |
| EP-3802514-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2021-04-14 | — | — | EP | claimed |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4140991-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220365086-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORPORATION | 2022-11-17 | — | — | US | disclosed |
| EP-3802514-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11390599-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3802514-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220365086-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | LUC7L2, LYPLAL1, GUSB | KDM4E 3154/4885MEN1 2157/4885KMT2A 2984/4885 |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | KDM4E 3154/4885MEN1 2157/4885KMT2A 2984/4885 |
| US-11390599-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | KDM4E 3154/4885MEN1 2157/4885KMT2A 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.